AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 231 min read$PHIO

Bitterman Robert J purchased $2K of PHIO

Bitterman Robert J (Chairman, Pres. & CEO) purchased 2,000 shares of Phio Pharmaceuticals Corp. (PHIO) at $1.03 on 2026-09-22.

Original reporting
SEC EDGAR · Bitterman Robert J
Published Sep 23, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 8:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PHIO
Neutral
high confidence
Mentioned
$PHIO
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHIONeutralLow
01

Why it matters

The purchase is too small to move the stock, but it confirms the CEO's continued stake.

02

Market read

Routine insider purchase with negligible trading relevance.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed in the filing.

Relevance 4/10Novelty 3/10Timing: post‑market 2026‑09‑22

Background

SEC Form 4 filing discloses insider transactions. Phio Pharmaceuticals is a micro‑cap biotech.

Company-level read

Ticker impact

$PHIONeutralHigh confidence
Context

Chairman Robert J. Bitterman purchased 2,000 PHIO shares at $1.0289 each on 2026-09-22.

Expected impact

Minimal impact; likely no immediate price move.

Evidence & confidence

The transaction size ($2k) is trivial relative to market cap, so market participants will not react strongly.

Counterpoint

What could challenge this read

Even small insider buys can signal confidence; some traders may view it as a subtle bullish cue.

Key entities

  • Company
    Phio Pharmaceuticals Corp.

    Biotech issuer of ticker PHIO.

  • Insider
    Robert J. Bitterman

    Chairman, President & CEO of Phio.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PHIO insider trading history →

Related articles

OCT 13
$PHIOMedAI 8/10

A cancer drug's first production-scale batch is complete; a clinical study is planned for early 2027.

Phio Pharmaceuticals (PHIO) announced the successful production of its first commercial-scale batch of PH-762, a cancer drug. The batch meets quality standards and will be used in a planned Phase 2b clinical trial set to begin in Q1 2027. The company's CEO highlighted this as a significant milestone, reducing development risks and supporting future clinical and regulatory steps.

stocktitan.net2 min
SEP 14
$PHIOMedAI 8/10

Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma

Phio Pharmaceuticals (PHIO) submitted a meeting request and briefing package to the FDA for PH-762, its lead clinical compound for cutaneous squamous cell carcinoma. The submission follows the completion of a Phase 1b trial and outlines plans for a Phase 2b study. The company expects to complete final activities for the next clinical phase by Q1 2027.

insidermonkey.com2 min
SEP 14
$PHIOMedAI 8/10

Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma

Phio Pharmaceuticals Corp. (PHIO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma Company Proposes Planned Phase 2b Neoadjuvant Study Following Successful Completion of Phase 1b Trial KING OF PR

SEC EDGAR 8-K1 min
AUG 6
$PHIOMedAI 8/10

Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Phio Pharmaceuticals (NASDAQ: PHIO) reported Q2 2026 results for the quarter ended June 30, 2026 and updated its PH-762 siRNA program. Cash fell to $13.0M from $21.0M at Dec. 31, 2025. R&D rose to $3.1M and net loss widened to $4.1M. PH-762 Phase 1b (22 patients) completed in March; FDA documentation is being prepared and an FDA meeting is planned for Q3 2026. The company also launched a $6.36M ATM equity program.

finanznachrichten.de7 min
AUG 6
$PHIOMed

Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update Strategic milestone advancements for lead clinical candidate PH-762

Phio Pharmaceuticals Corp. (PHIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update Strategic milestone advancements for lead clinical candidate PH-762 Initiation of commercial scale API, long term non-clinical toxicology, completion of Phase 1b pharmacology, and

SEC EDGAR 8-K6 min